We have demonstrated recently that in menopausal women and in ovariectomized rats the deficiency of circulating oestrogens impairs vasoactive intestinal peptide (VIP) efficacy in stimulating prolactin (PRL) release. The present study was designed to investigate whether the lack of VIP-induced PRL release after ovariectomy is a consequence of a defect at the receptor-transductional or post \ x=req-\ transductional level. For 
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In a previous study carried out on fertile and menopausal women we showed a marked increase of plasma PRL concentration after thyrotrophin-releasing hormone (TRH) injection in both groups. On the contrary, VIP injection significantly increased plasma PRL levels in fertile women but not in menopausal women (8) . These results were transferred to animal models and cell cultures in which it was possible to show that the increase of PRL levels induced by VIP (but not that induced by TRH) is absent in ovariectomized (ovx) rats but can be restored by oestrogen treatment (9) . This finding suggested that in men and rats the intracellular machinery responsible for mammotroph sensitivity to VIP requires oestrogens.
Since the well-established effect of oestrogens in the regulation of both cell growth (10, 11) In a previous paper we reported that ovariectomy suppresses the mammotroph responsiveness to direct VIP application. This effect appeared to be linked to a prolonged deficit of circulating oestrogen in ovx rats and was shown to be specific for VIP because mammotroph sensitivity to TRH was only poorly reduced (9) .
In the present study we (20, 21) , VIP was shown to potentiate corticotrophic-releasing factor-induced ACTH release in a dose-dependent manner (20) . Moreover, Bluet-Pajot et al. (22) (27) 
